Pyruvate transport into mitochondria is a key step in energy metabolism. Zaprinast is a well-known phosphodiesterase inhibitor. Results: Zaprinast has a strong influence on pyruvate transport into mitochondria. http://www.jbc.org/cgi
INTRODUCTION
Pyruvate is a critical metabolite that links glycolysis with the mitochondrial tricarboxylic acid (TCA) cycle, and it is a hub for synthesis of amino acids, carbohydrates and fatty acids. Pyruvate enters mitochondria through a recently identified mitochondrial pyruvate carrier (MPC), a 150 kD complex of MPC1 and MPC2, located on the inner mitochondrial membrane (1,2). Knockout of MPC1 in Drosophila elevates pyruvate and decreases mitochondrial TCA intermediates (1). Children with mutations in a conserved region of human MPC1 have symptoms of lactic acidosis and hyperpyruvatemia (1,3). MPC inhibitors have been identified in the past 40 years including the classical α-cyanocinnamate analogs, UK5099, α-cyano-4-hydroxycinnamic acid (4CIN) (4) , and insulin sensitizer thiazolidinedione (TZD) (5-7).
Zaprinast, a lead compound used for the development of Sildenafil (Viagra), is a well-established inhibitor of cGMP specific phosphodiesterase (PDE). PDEs hydrolyze the cyclic phosphate bond in cAMP and cGMP and they function to inactivate cyclic nucleotide signaling pathways. Zaprinast has been used as a tool to study PDE5 and PDE6 (8) (9) (10) (11) . PDE5, PDE6 and PDE9 are cGMP specific; PDE4, PDE7 and PDE8 are cAMP specific; and the rest of the members of the PDE family have dual specificity (12) . Zaprinast is the only drug that inhibits PDE6 more potently than PDE5 (13) . PDE6 is primarily expressed in retinal photoreceptors where it is responsible for light-dependent signal transduction. Mutations in the Pde6a, b, or c genes all cause retinal degeneration in humans (14) (15) (16) and in mouse models (17, 18) . We performed a study intended to use Zaprinast to simulate the effects of PDE6 dysfunction in an ex vivo retinal degeneration model. We treated cultured mouse retinal explants with Zaprinast, but we found unexpectedly that Zaprinast is a potent inhibitor of mitochondrial pyruvate transport. This led to a novel and important finding, the focus of this report, that inhibition of mitochondrial pyruvate transport triggers dramatic metabolomic changes in neuronal tissues that severely alter the concentrations of glutamate and aspartate. 13 C tracers and reagents were purchased from Sigma unless otherwise specified. Animals C57BL/6 mice (6-8 weeks old) and C3Sn. BLiA-Pde6b+/DnJ (PDE6b+) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). C3H retinal degeneration (rd1) mice, which bear a Pde6b mutation were provided by Dr. Thomas A Reh, University of Washington. Pde6b+ mice were used as the background control for rd1 mice. Cyclic nucleotide gated channel 1 knock-out (Cngb1 -/-) mice on C57BL/6 background were obtained from the Institute for Ophthalmic Research, Tuebingen, Germany (19, 20 
EXPERIMENTAL PROCEDURES

Retina isolation and culture
Mice were euthanized using CO 2 and cervical dislocation. The eyes were removed and retinas were separated from retinal pigment epithelium in cold HBSS. The retina was cultured in Krebs-Ringer/HEPES/ bicarbonate buffer (KRB) (22) with glucose (5 mM), or other 13 C labeled substrate (5 mM) in a 37 o C 5% CO 2 incubator.
cGMP Assay
Two mouse retinas were homogenized in 300 μl of 0.1N HCL. After centrifugation, 100 μl of the supernatant was assayed for cGMP by using a Direct cGMP ELISA kit from Enzo Life Sciences, Inc. (Farmingdale, NY).
Gas Chromatography/Mass Spectrometry (GC/MS) analysis of metabolites
Individual mouse retina was rinsed in cold 0.9% NaCl and snap frozen in liquid nitrogen. The retina was homogenized in a 700:200:50 cold mixture of methanol/chloroform/water with 5 nmol internal standard methylsuccinate. After centrifugation, the supernatant was dried under vacuum, derivatized and analyzed by GC-MS (Agilent 7890/5975C) (22). The peaks were analyzed using Agilent data analysis software. The measured distribution of mass isotopomers was corrected for natural abundance of 13 
Glucose concentration assay
Glucose in the culture medium was measured using an Amplex® Red Glucose /Glucose Oxidase Assay Kit. (Invitrogen).
Pyruvate dehydrogenase activity (PDH) activity assay PDH activity was measured using NADH cycling assay in the presence of diaphorase to reduce the generated NADH, and MTT as an electron acceptor (27). Purified PDH protein from pig heart was incubated with 1 mM MgCl 2 , 5 mM CaCl 2 , 5 mM l-carnitine, 0.2 mM thiamine pyrophosphate, 0.1mM CoA, 2.5 mM NAD + , 1 mM MTT and 1 U/ml diaphorase in 50 mM HEPES/KOH buffer pH 7.5 at 30 o C. 5 mM pyruvate was added into the mixture to start the reaction and the plate was read at 570 nm every 10 sec for 10 min. The Δ570 nm with maximum linear rate was used for calculating the enzyme activity.
Statistical analysis
Data are expressed as mean ± SEM. Significance of differences between means was determined by unpaired two-tailed t-tests or ANOVA with an appropriate post-hoc test. A p-value < 0.05 was considered to be significant.
RESULTS
Zaprinast causes depletion of glutamate and accumulation of aspartate-
We began the experiments with the intention of identifying the metabolomic signature of PDE6 inhibition. We isolated mouse retinas and incubated them with or without Zaprinast in the presence of 5 mM glucose and then extracted metabolites for GC/MS analysis. We then determined the concentration of Zaprinast required to inhibit PDE activity in mouse retinas. The concentration of Zaprinast required to cause accumulation of cGMP in the retina is in the range of 20~200 μM (Supplemental Fig. 1A ). We also found large changes in several metabolite levels at 200 μM (Fig. 1A ). Glutamate and aspartate had the largest changes: about 5 fold decrease and increase, respectively. The effects on both glutamate and aspartate were first detectable at 30 minutes after addition of Zaprinast, became more apparent at 60 minutes, and remained constant from 2 to 6 hours (Supplemental Fig.  1B-C) . We reasoned that the change of these two metabolites might be primarily responsible for the overall change of metabolic profile since aspartate-derived metabolites, malate, methionine, cysteine and N-acetyl-aspartate increased whereas glutamate-derived metabolites, glutamine and α-ketoglutarate (αKG), decreased. We considered that glutamate in the retina might decrease because it is released into the medium. However, both glutamate and aspartate were undetectable in the incubation medium. Pyruvate increased by about 2-3 fold in response to Zaprinast in both retina and medium, but lactate did not change (Fig.  1A-B ). Glucose deprivation (22,28) causes similar changes of glutamate and aspartate levels in retina and brain slices. Therefore, we tested the effect of Zaprinast on glucose consumption. The retina consumed about 1.2 μmoles per hour per retina. Zaprinast did not affect the rate of glucose consumption (Fig. 1C) .
The effect of Zaprinast on glutamate and aspartate is independent of PDE inhibition-To investigate the relationship between PDE6 inhibition and the metabolic effects of Zaprinast, we compared the concentrations of Zaprinast required to inhibit PDE in the retina with the concentration required to cause glutamate to decrease. We found that Zaprinast increases cGMP at 50 μM and 100 μM, and increases both cGMP and cAMP at 200 μM. This indicates that Zaprinast inhibits PDE6 specifically between 50-100 μM but it inhibits other PDEs at 200 μM ( Fig. 2A) . Surprisingly, Zaprinast decreased glutamate and increased aspartate at much lower concentrations beginning at 2 μM (Fig. 2B ).
To test whether cyclic nucleotide-gated channels and Ca 2+ are involved in the decrease of glutamate, we used the retina from Cngb1-/-mice in which the rising cGMP could not activate CNG channels to cause depolarization and elevation of intracellular free Ca 2+ (19, 29) . Remarkably, Zaprinast decreased glutamate and increased aspartate in Cngb1-/-retina (Fig. 2C) . Furthermore, neither of the cell-permeable cGMP analogues, 8-Br-cGMP and CPT-cGMP, nor inhibitors of PKG and PKA, changed the levels of glutamate and aspartate in the retina (Supplemental Fig. 2 ). These findings suggested that Zaprinast increases aspartate and lowers glutamate by a different mechanism than we expected, i.e. in a PDE6-independent fashion.
As further confirmation that the metabolic effects of Zaprinast occur independently of PDE6 inhibition, we applied Zaprinast to the retina from rd1 mice that were two months old. The rd1 mutation causes almost all PDE6 expressing photoreceptors to die and disappear by one month of age and thus abolishes PDE6 activity. We found that glutamate and aspartate levels in rd1 retina are lower than normal, consistent with photoreceptors being a major source of these amino acids in normal retinas. We also found that Zaprinast potently decreases glutamate and increases aspartate in rd1 retina suggesting that Zaprinast acted at a site distinct from PDE6 (Fig.  2D ). As further confirmation that the effect of Zaprinast on glutamate and aspartate was not through PDE, we evaluated the effect of Sildenafil, another PDE5/6 inhibitor. Sildenafil between 0.1-50 μM robustly increased cGMP in WT retina but did not have a significant effect on glutamate or aspartate ( Fig. 2E-F ). Taken altogether, these results show unambiguously that the effect of Zaprinast on glutamate and aspartate occurs independently of PDE inhibition.
The effect of Zaprinast on glutamate and aspartate occurs independently of GPR35
activation-Zaprinast also has been identified as a potent agonist of G protein-coupled receptor 35 (GPR35) (30,31). GPR35 is expressed predominantly in spleen, immune cells, and gastrointestinal tissues, but expression in eye also has been reported (32,33). To test whether GPR35 contributes to the metabolic effect of Zaprinast we pre-incubated the retina with a GPR35 antagonist, CID 2745687, for 30 min followed by an additional 30 min of Zaprinast treatment. CID 2745687 did not block the effect of Zaprinast on glutamate and aspartate. Furthermore, the GPR35 agonist, pamoic acid, did not change glutamate or aspartate levels (Supplemental Fig. 3 ). These results show that GPR35 was not responsible for the observed Zaprinast effects. 13 C to synthesize acetyl-CoA and the 2 labeled carbons appear in most TCA intermediates in the first round of the TCA cycle (Fig. 3A) . In the second cycle, citrate gains a total of 4 labeled carbons and the rest of the intermediates have either 3 or 4 carbons labeled due to the loss of CO 2 at one of two different positions (Supplemental Fig. 4A ). Zaprinast did not change the 13 C enrichment in pyruvate and lactate.
Zaprinast blocks entry of glucose-derived
However, the enrichment of glutamate, aspartate and TCA intermediates was much lower after Zaprinast treatment (Fig. 3B) (Fig. 5A-D) . However, Zaprinast did not block O 2 consumption fueled by glutamate or succinate. This is consistent with our isotopic labeling experiment in which Zaprinast did not inhibit glutamate oxidation. We next tested the hypothesis that Zaprinast blocks pyruvate transport by inhibiting MPC. Similar to Zaprinast, MPC inhibitor UK5099 blocked pyruvate-driven but increased glutamate and succinate-driven oxygen consumption. (Fig. 5E-F, Supplemental Fig.  7A-B) . There was no significant difference in rate of oxygen consumption between Zaprinast and UK5099. (Supplemental Fig. 7C-D) .
Zaprinast inhibits MPC but not PDH-To confirm that Zaprinast targets the MPC, we measured MPC activity directly using isolated mouse liver mitochondria. The MPC kinetics we measured are similar to previous reports (2,4). We measured flux of [2- 14 C]pyruvate transport into isolated liver mitochondria. We confirmed the specificity of the assay by showing that 10 mM unlabeled pyruvate inhibits uptake of the labeled pyruvate.
(Supplemental Fig. 8A-B) . Zaprinast inhibits pyruvate uptake (Fig. 6A ) at a dose (Fig. 6B ) that is in similar to the dose required for its effect on glutamate and aspartate in the retina ( Fig. 2A) .
To exclude the possibility that Zaprinast might inhibit PDH, we incubated pure PDH enzyme with Zaprinast or the known PDH inhibitor 3-fluropyruvate (3-FP). Zaprinast did not affect the activity of PDH at any concentration tested. In contrast, 3-FP effectively inhibited PDH activities (Fig. 6C ).
To confirm that the metabolic effect of Zaprinast is caused by MPC inhibition and not by inhibition of PDH activity, we bypassed MPC by adding [ 13 C 3 ]pyruvate to mitochondria with disrupted membranes (See Experimental Procedures). In this experiment pyruvate is accessible directly to PDH. Both Zaprinast and UK5099 decrease the amount of labeled citrate produced by mitochondria with intact membranes, but they have no effect on citrate formation when mitochondrial membranes are disrupted (Fig. 6D ).
As expected, disruption of the mitochondrial membrane blocks the ability of either Zaprinast or UK5099 to stimulate depletion of glutamate (Fig.  6D ). (Fig. 7A) . AGC1 allows the carbons from aspartate to bypass the conventional "complete" version of the TCA cycle.
In the absence of AGC1 the carbons that would normally be used to make aspartate are forced into the complete TCA cycle, thus decreasing the levels of the amino acid in AGC1 -/-retina. In the absence of AGC1, the malate aspartate shuttle becomes impaired and pyruvate is diverted to produce lactate and not acetyl-CoA. Consistently, the retina from AGC1 -/-mice had lower levels of aspartate and pyruvate than WT mice (Fig. 7B ) (35).
We investigated whether AGC1 plays a role in the Zaprinast effect and found that it does not (Fig.  7B ). When incubated with [ 13 C 6 ]glucose, AGC1
+/-or AGC1 -/-retinas have 13 C enrichment similar to WT except that the overall levels of pyruvate and aspartate are lower than normal (Supplemental Fig.  9 ). AGC1 deficiency impaired production of pyruvate, citrate, glutamate and especially aspartate, consistent with a previous study of AGC1-deficient neurons (35). Nevertheless, Zaprinast still decreased labeling of glutamate from glucose and increased labeling of aspartate and pyruvate in both AGC1
+/-and AGC1 -/-retinas ( Fig. 7C-F Unlabeled aspartate accumulates in mitochondria during Zaprinast treatment (Fig. 8A-C) . To confirm that Zaprinast decreases utilization of aspartate, we incubated the retina with labeled aspartate in the presence of glucose. During 1 hour without Zaprinast, aspartate contributed 13 C to ~30% of glutamate and other TCA cycle intermediates ( Fig. 8D-E) . However, Zaprinast blocked the incorporation of 13 C from aspartate into citrate and glutamate ( Fig. 8F-H) . This reflects diminished acetyl-CoA synthesis in mitochondria, consistent with inhibition of pyruvate carrier activity by Zaprinast. In addition, the decreased lactate/pyruvate ratio (Fig. 8I ) might lower cytosolic reducing power, which cause accumulation of aspartate by reversing the malate dehydrogenase reaction in the cytoplasm to cause accumulation of aspartate (Fig. 9) . Consistent with this, we found that Zaprinast decreases NADH levels in the retina (Fig. 8J) .
DISCUSSION
We demonstrated that the well-known PDE5/6 inhibitor Zaprinast blocks pyruvate transport into mitochondria by a mechanism that is independent of PDE inhibition. Inhibition of pyruvate transport either by Zaprinast or by known MPC inhibitors decreases de novo synthesis of glutamate from glucose and aspartate, and it increases the net oxidation of glutamate into aspartate. The result is severe depletion of glutamate and several fold accumulation of aspartate. These findings are significant because glutamate is important as a fuel for energy production, as a neurotransmitter, and as a substrate for glutathione synthesis. We confirmed by direct measurements of pyruvate uptake that Zaprinast dose-dependently inhibits MPC activity in isolated mitochondria. MPC is an integral membrane protein in the mitochondrial inner membrane. To rule out any effect on PDH activity we measured the effect of Zaprinast on mitochondria whose membrane structure was disrupted by detergent. There was no effect of Zaprinast on these preparations. This shows that Zaprinast does not target PDH nor citrate synthase. We also confirmed directly that Zaprinast does not affect the activity of purified PDH. In our MPC activity assay some labeled pyruvate may have been metabolized. We did not correct for this or for labeled pyruvate that may have been at the surface of the pellets. This may explain why the pyruvate uptake continued for more than 1 min and neither cold pyruvate nor Zaprinast completely eliminated the labeled pyruvate in mitochondrial pellet. Future studies should address the structural basis for Zaprinast inhibition of MPC and whether Zaprinast directly binds MPC. In the retina, more than 60% of glutamate de novo synthesis depends on transaminases such as alanine transaminase, aspartate transaminase and branched amino acids transaminase (49). However, only aspartate and not alanine or branched amino acids increase with Zaprinast. Glutamate may also decarboxylate into GABA, but Zaprinast does not increase GABA content in the retina. Therefore, the amino group of aspartate most likely comes from glutamate transamination (49).
In conclusion, independently of its known effects on PDE, Zaprinast potently inhibits pyruvate transport into mitochondria, impairing glucose oxidation and mitochondrial function. Inhibition of pyruvate transport mimics the effect of hypoglycaemia: accumulation of aspartate, depletion of glutamate and glutamine, and mitochondrial dysfunction. Our findings suggest a new route for pharmacological application and development of Zaprinast, they highlight the physiological influence of MPC on metabolism, and they contribute to understanding of the basic metabolic reaction to hypoglycaemia. Inhibition of MPC by Zaprinast or UK5099 blocks entry of pyruvate into mitochondria, which decreases production of acetyl-CoA, citrate, αKG, glutamate and NADH, and increases oxaloacetate and aspartate. Aspartate exits mitochondria in exchange for glutamate via AGC1 to oxidize more glutamate into aspartate. In the cytosol, the glutamate may be transaminated into αKG which exchanges with malate or enters the mitochondria through either AGC1 or GC. Metabolites with red represent increases, blue represent decrease, and black represent unchanged or untested. Thick lines represent more flux in that direction. GOT1, cytosolic glutamate oxoglutarate transaminase; GOT2, mitochondrial glutamate oxoglutarate transaminase; GC, glutamate carrier.
